Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Abstract In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that
included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to …

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …

Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia
(CML) are: avoid progression to accelerated phase or blast crisis CML such that patients …

Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase
chronic myeloid leukemia (CML-CP) who received≥ 2 prior tyrosine kinase inhibitors or …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic
myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an …